Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Clene Inc.NASDAQ: CLNN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $8.09M (cash outflow) rose 977.4% year over year, ahead of the +15.3% change in trailing-twelve-month net income. Sequentially, it fell 12.3% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Net income amounted to 13086.5% of revenue in FY2025, up 1566.0 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$21.36M (-18.4%) for the fiscal year ending Dec 2026, a step up from the -33.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.09M-12.3% QoQ
Last fiscal yearDec 2025
-$26.17M-33.6% YoY
LTMMar 2026
-$33.51M+15.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+977.4%-27.2%-1004.6 pp
1 year-33.6%-18.4%+15.2 pp
3-year CAGR-4.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(26.17M) USD
Year-over-year change
+33.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 net income of $33.51M is the 8th largest of the 11 companies compared; the peer median is $45.05M.
  • Its year-over-year change of +15.3% is the 6th highest of 11, against a peer median of +10.0%.
  • Net income amounts to 25009.7% of revenue for CLNN, versus a peer median of 313.8%.
CLNN Competitors Peer median
Net Income for CLNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$124.13M -44.6%-16.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$113.22M -48.4%+6.6%—
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M +489.6%——
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M +26.1%-14.6%44.8%
CNTBConnect Biopharma Holdings LimitedFY2025$55.48M +255.0%-21.8%86687.5%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M -29.4%-21.8%4987.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.23M +45.6%+34.5%—
CLNNClene Inc.LTM Mar 2026$33.51M +15.3%-4.4%25009.7%
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.17M -3.2%-31.5%339.3%
COYACoya Therapeutics, Inc.LTM Mar 2026$21.13M +23.3%+20.1%266.1%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$20.6M -67.7%-30.2%288.3%
Peer median (excluding CLNN) $45.05M+10.0%-16.7%313.8%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
Deferred Income Tax00000
Stock-Based Compensation12.38M8.51M9.12M7.95M6.38M
Change in Working Capital1M(1.54M)(191K)3.21M(3.35M)
Accounts Receivables(28K)(140K)46K79K64K
Inventory150K(2K)6K(31K)31K
Accounts Payables1.27M285K(1.51M)(264K)(348K)
Other Working Capital(386K)(1.68M)1.27M3.43M(3.1M)
Other Non-Cash Items(39.23M)(17.09M)8.7M5.27M3.1M
Operating Cash Flow(34.62M)(39.01M)(30.17M)(21.33M)(18.55M)
Capital Expenditures(1.33M)(5.18M)(330K)(15K)(39K)
Acquisitions (Net)00000
Purchases of Investments0(24.61M)(6.17M)(6.17M)0
Sales of Investments019.63M5M12.5M0
Other Investing Activities00000
Investing Cash Flow(1.33M)(10.16M)(1.5M)6.32M(39K)
Debt Repayment19.84M5.56M269K(10.9M)1.12M
Common Stock Issued9.25M11.46M42.09M9.24M10.4M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.98M)229K(200K)124K0
Financing Cash Flow27.11M17.25M42.16M(1.53M)11.52M
Effect of Forex Changes(85K)(30K)(4K)(127K)101K
Net Change in Cash(8.93M)(31.96M)10.49M(16.67M)(6.97M)
Free Cash Flow(35.96M)(44.19M)(30.5M)(21.34M)(18.59M)

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.